The newly launched ‘2020 Cortellis Drugs to Watch’ list identifies 11 drugs that are set to enter the market in 2020 and reach more than $1 billion in sales by 2024. Only 3 of 11 drugs are focusing on oncology and it is evident that pharmaceutical companies are also investing on other indications and focusing more on clinical unmet needs and conditions with current treatments hampered by safety, efficacy, convenience or other issues.
Many drugs anticipated to be potential blockbuster are approved with special regulatory designations. The drugs are expected to face diverse competition ranging from a single strong opponent to a plethora of different agents, each with its own strengths and weaknesses.Thus, there will be substantial pressure on these therapeutics to differentiate from existing products.
Considering the current pandemic of COVID-19, we will also discuss the potential drugs/vaccines in active development and summarize scientific research on COVID-19.